Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03322995 · ClinicalTrials.gov registry record · Phase 2
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
A Phase 2 study of Pancreatic Cancer, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT03322995 is a Phase 2 study of Pancreatic Cancer that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 125 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03322995, a Phase 2 study of Pancreatic Cancer, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.
Conditions Studied
Interventions
- RADIATION Chemoradiation
- DRUG First-line Chemotherapy
- DRUG Second-line Chemotherapy
Study Locations (1)
Wisconsin
- Froedtert & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2032-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03322995
The ClinicalTrials.gov registry entry for NCT03322995 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (68% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Chemoradiation is the first listed.
NCT03322995 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03322995 about?
NCT03322995 is a clinical study titled "Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial". This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.
What is the current status of trial NCT03322995?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2018-06-21. Estimated completion is 2032-06-01.
What conditions does trial NCT03322995 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT03322995?
The interventions under investigation include: Chemoradiation (RADIATION), First-line Chemotherapy (DRUG), Second-line Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03322995?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03322995 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.